Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06545955 · ClinicalTrials.gov registry record · Phase 3
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
A Phase 3 study of Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, sponsored by Ferring Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
- 20
- Study locations
NCT06545955 is a Phase 3 study of Non-muscle Invasive Bladder Cancer With Carcinoma in Situ that is actively recruiting participants, run by Ferring Pharmaceuticals. The registered enrollment target is 250 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT06545955, a Phase 3 study of Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, is actively recruiting participants, sponsored by Ferring Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T1 achieved a complete response (CR) at 3 months. In this trial, the safety and efficacy of intravesical instillation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy will be evaluated in participants with NMIBC CIS (± high-grade Ta/T1).
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Docetaxel
- DRUG Gemcitabine
- DRUG Nadofaragene Firadenovec
Study Locations (20)
California
- American Institute of Research - Los Angeles
- USC Kenneth Norris Jr Cancer Hospital - Los Angeles
- University of California, Irvine - Orange
- Genesis Research, LLC - San Diego - San Diego
Colorado
- Advent Health - Denver
- Colorado Urology - St. Anthony Hospital Campus - Lakewood
Georgia
- Emory University - Atlanta
- Georgia Urology - Atlanta
Maryland
- Anne Arundel Urology, PA - Annapolis
- Chesapeake Urology Research Associates - Hanover
New York
- Roswell Park Cancer Institute - Buffalo
- Great Lakes Physician PC d/b/a Western new York Urology Associates - Cheektowaga
Connecticut
- Yale School of Medicine - New Haven
District of Columbia
- Medstar Georgetown University Hospital - Washington D.C.
Florida
- Sarasota Memorial Healthcare System - Sarasota
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2024-10-01 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06545955
The ClinicalTrials.gov registry entry for NCT06545955 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-muscle Invasive Bladder Cancer With Carcinoma in Situ appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT06545955 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Colorado, Georgia.
Frequently Asked Questions
What is clinical trial NCT06545955 about?
NCT06545955 is a clinical study titled "A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer". The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T1 achieved a complete response (CR) at 3 months. In this trial, the safety and efficacy of intravesical instillation of nadofaragene firaden...
What is the current status of trial NCT06545955?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2024-10-01. Estimated completion is 2030-12-31.
What conditions does trial NCT06545955 study?
This clinical trial studies the following conditions: Non-muscle Invasive Bladder Cancer With Carcinoma in Situ.
What interventions are being tested in trial NCT06545955?
The interventions under investigation include: Pembrolizumab (DRUG), Docetaxel (DRUG), Gemcitabine (DRUG), Nadofaragene Firadenovec (DRUG).
Who is sponsoring clinical trial NCT06545955?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06545955 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.